Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Accord Healthcare receives positive CHMP opinion for IMULDOSA®, ustekinumab
CHMP issues positive opinion for Imuldosa®, a biosimilar to Stelara®, based on comprehensive data confirming therapeutic equivalence and comparable safety. This paves the way for EU authorization in a market valued at €2.9 billion. Intas holds global commercialization rights, excluding Japan, Korea, and certain Asian countries.
Accord BioPharma's Stelara® Biosimilar Imuldosa™ Approved by FDA
FDA approved Accord BioPharma’s Imuldosa™ (ustekinumab-srlf), the fifth Stelara® biosimilar, developed by Dong-A ST and Meij Seika Pharma, with Accord handling U.S. commercialization. Imuldosa™ can launch in the U.S. no later than May 15, 2025, under a 2023 settlement. Stelara®, chosen for Medicare price negotiations, will see a 66% discount from its 2023 list price, potentially impacted by biosimilar launches in early 2025. Johnson & Johnson reported $6.97B in U.S. Stelara® sales in 2023.
Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab ...
Accord announces CHMP positive opinion for Imuldosa®, a Stelara® biosimilar, enhancing biosimilar portfolio and autoimmune franchise. Imuldosa® is Accord's 5th biosimilar in the EU, with 10 more in development.
Overcoming Pharma's Major Pain Points and Pitfalls With AI
AI revolutionizes drug discovery by streamlining clinical trials, optimizing workflows, and uncovering new drug applications, promising faster, cost-effective development and expanded therapeutic benefits.
Johnson & Johnson Details Six Ways it Utilizes AI
Johnson & Johnson uses AI to detect disease early, accelerate drug discovery, assist clinical trial recruitment, map patient anatomy, predict surgical tools, and improve surgeon performance, aiming to deliver faster, more personalized care.
Accelerating Drug Discovery With AI for More Effective Treatments
AI can revolutionize drug discovery by speeding up development, cutting costs, and enhancing treatment options, but addressing its limitations is crucial for future success.
FDA Can Approve Cheaper Copycat Of Heart-Failure Drug Entresto, Judge Says
Judge allows FDA to approve generic version of Novartis' heart-failure drug Entresto. HIV-positive individuals can safely receive HIV-donated kidneys. J&J cuts neurology and psychiatry programs. FDA's accelerated approval pathway faces high-profile failures. Lab-grown blood vessels by Humacyte could revolutionize trauma treatment.
Johnson & Johnson announces positive results from phase 2/3 Vibrance-MG study of nipocalimab plus standard of care for generalized myasthenia gravis in adolescents
Johnson & Johnson's phase 2/3 Vibrance-MG study shows nipocalimab plus standard of care (SOC) effectively controls generalized myasthenia gravis (gMG) in adolescents, with significant IgG reduction and clinical benefits. The study's positive results will be presented at the MGFA Scientific Session. Nipocalimab's potential as a treatment for adolescents with gMG is highlighted, as there are currently no approved advanced treatments for this population in the U.S.
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug
Nurix Therapeutics appoints Anil Kapur to its board of directors, effective October 15, 2024. Kapur brings over 25 years of executive experience in pharmaceutical and biotech companies, with expertise in commercial operations and launching novel drugs in hematology and oncology. His notable achievements include launching blockbuster drugs Imbruvica and Darzalex at Johnson & Johnson. Nurix plans to advance NX-5948 into pivotal clinical testing in 2025 and prepare for future commercialization.
Nipocalimab Demonstrates Sustained Disease Control in Adolescents with Generalized Myasthenia Gravis
Johnson & Johnson's nipocalimab showed sustained disease control in adolescents with generalized myasthenia gravis, with 70% reduction in IgG and no serious AEs, suggesting a promising treatment option for this age group.
© Copyright 2024. All Rights Reserved by MedPath